"Janssen Research & Development is committed to discovering and bringing to market innovative therapeutic solutions for people with brain disorders and pain."
Husseini Manji, M.D., F.R.C.P.C.
Global Head, Neuroscience
The Janssen Research & Development Neuroscience team is focused on Alzheimer’s disease and mood disorders, and we continue our legacy work in schizophrenia and chronic pain. While our primary interest is in programs aimed at the discovery and development of novel medicines, we are also interested in new biomarkers and companion diagnostics to drive earlier and more accurate diagnosis, treatment response and outcome prediction in these core focus areas.
We have a strong interest in biological molecules and in developing novel strategies to address blood-brain barrier challenges to improve central nervous system penetration of large-molecule medicines; for example, through receptor-mediated transcytosis and intra-nasal delivery methods.
We also seek integrative solutions to achieve earlier intervention and adherence, and prevent relapse. Examples include non-pharmaceutical cognitive enhancing therapies and remote monitoring technologies.